Mitigating Mold Contamination Risk in Biopharmaceutical Facilities

Published by industry expert Maik Jornitz in the PDA Journal of Pharmaceutical Science and Technology, this white paper examines the significant mold contamination risks that are directly influenced by the building materials used in biopharmaceutical cleanroom construction. Gypsum wall systems, while common in general construction, are inherently porous and hygroscopic, meaning they absorb moisture and degrade under repeated exposure to harsh disinfectants. Over time, this creates conditions that support mold growth, making remediation extremely difficult and costly. Regulatory agencies including the FDA and EMA have increasingly cited gypsum walls in inspection findings for their inability to withstand routine sanitization and their tendency to harbor moisture and microbial contamination.

Jornitz makes the case that uPVC cleanroom panels offer a superior alternative, engineered specifically for controlled environments. Their non-porous, moisture-resistant structure eliminates the internal cavities where mold typically thrives, and their seamless, heat-welded joints create a continuous surface that is easy to clean and chemically resistant to aggressive disinfectants. While uPVC carries a higher upfront cost than gypsum, the long-term economics strongly favor the investment reducing contamination risk, costly shutdowns, regulatory findings, and ongoing maintenance. For biopharmaceutical facilities committed to GMP compliance and product integrity, Jornitz concludes that transitioning to uPVC panels is a strategic and high-impact decision.

Learn more about Maik Jornitz and our leadership team.